Bridgewater, New Jersey /Lausanne, Switzerland, June 2021 – Diabetes affects more...
Bridgewater, New Jersey /Lausanne, Switzerland, June 2021 – Diabetes affects more than 34 million children and adults in the United States and 463 million around the world. Approximately 90-95% of these individuals have type 2 diabetes which is usually caused by excess body weight and physical inactivity1, as well as genetic predisposition.
Nestlé Health Science is addressing ways to prevent type 2 diabetes with its symposium on June 27, 2021 at the American Diabetes Association Virtual 81st Scientific Sessions (ADA 2021) on “Nutritional Approaches for the Prevention and Remission of Type 2 Diabetes and Weight management.” Dr. Ian J. Neeland, of the Harrington Heart and Vascular Institute, and Professor Roy Taylor, of Newcastle University and Newcastle Hospitals NHS Trust will discuss the role of nutrition intervention on the pathophysiology and management of obesity, type 2 diabetes and co-morbidities including metabolic-associated fatty liver disease (MAFLD).
Nestlé Health Science will also host a personalized virtual booth, providing attendees the opportunity to interact with Nestlé Health Science experts and learn more about our research and innovation for diabetes and weight management interventions through the ADA TV Thought Leader film.
Additionally, a late-breaking abstract2 entitled “Very-low dose pre-meal whey protein microgels reduce postprandial glucose in type 2 diabetes: a randomized, placebo-controlled crossover study” will present the results from our clinical trial on how a small, low-caloric pre-meal shot of whey proteins, developed using a new technology by Nestlé Health Science, can help benefit the postprandial metabolic profile in people with type 2 diabetes.
“Nestlé Health Science is committed to research in diabetes and weight management,” said Hans-Juergen Woerle, Chief Scientific & Medical Officer of Nestlé Health Science. “Our activities at ADA 2021 underscore our commitment to develop interventions aimed to enhance nutritional efficacy, and weight reduction, in people affected by metabolic disease, as well as to better understand how people with type 2 diabetes can put their disease into remission.”
To attend the symposium, please register via the ADA website: https://professional.diabetes.org/scientific-sessions
- WHO fact sheet. https://www.who.int/news-room/fact-sheets/detail/diabetes Accessed June 2021
- de Gregório LH, Neeland IJ, Zagury R, Ahrén B, Neutel J, et al. Very-low dose pre-meal whey protein microgels reduce postprandial (PP) glucose in type 2 diabetes: a randomized, placebo-controlled crossover study. ADA 2021, LB-37